EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSCAFG00020001913
Gene Symbol: SCN7A
3 Cross references
85 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSCAFG00020001333
Gene Symbol: SCN9A
3 Cross references
109 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSCAFG00020021308
Gene Symbol: SLC10A2
3 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSCAFG00020013770
Gene Symbol: SLC18A2
3 Cross references
222 Possible Orthologues:

Solute Carrier Family 22 Member 11

Ensembl ID : ENSCAFG00020014250
Gene Symbol: SLC22A11
3 Cross references
891 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSCAFG00020014353
Gene Symbol: SLC22A12
3 Cross references
475 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSCAFG00020013234
Gene Symbol: SLC22A6
3 Cross references
495 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSCAFG00020013254
Gene Symbol: SLC22A8
3 Cross references
304 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSCAFG00020012121
Gene Symbol: SLC29A1
3 Cross references
280 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSCAFG00020003745
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSCAFG00020020436
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSCAFG00020007634
Gene Symbol: SLC6A1
3 Cross references
279 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).